BR112023002301A2 - Anticorpos contra ilt2 e uso dos mesmos - Google Patents

Anticorpos contra ilt2 e uso dos mesmos

Info

Publication number
BR112023002301A2
BR112023002301A2 BR112023002301A BR112023002301A BR112023002301A2 BR 112023002301 A2 BR112023002301 A2 BR 112023002301A2 BR 112023002301 A BR112023002301 A BR 112023002301A BR 112023002301 A BR112023002301 A BR 112023002301A BR 112023002301 A2 BR112023002301 A2 BR 112023002301A2
Authority
BR
Brazil
Prior art keywords
ilt2
antibodies against
methods
antibodies
same
Prior art date
Application number
BR112023002301A
Other languages
English (en)
Inventor
Anna Fridman-Dror
Avidor Shulman
Haves Ziv Dana
Dror Alishekevitz
Ilana Goldshtein
Ilana Mandel
Motti Hakim
Tehila Ben-Moshe
Tsuri Peretz
Yair Sapir
Original Assignee
Biond Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2020/050889 external-priority patent/WO2021028921A1/en
Application filed by Biond Biologics Ltd filed Critical Biond Biologics Ltd
Publication of BR112023002301A2 publication Critical patent/BR112023002301A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

anticorpos contra ilt2 e uso dos mesmos. a presente invenção refere-se a anticorpos monoclonais anti-ilt2 ou fragmentos de ligação ao antígeno dos mesmos, bem como composições farmacêuticas compreendendo os mesmos e métodos de produção dos mesmos. também são fornecidos métodos de tratamento de câncer usando os anticorpos ou composições da presente invenção. métodos de seleção de pacientes também são fornecidos.
BR112023002301A 2020-08-12 2021-08-11 Anticorpos contra ilt2 e uso dos mesmos BR112023002301A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/IL2020/050889 WO2021028921A1 (en) 2019-08-12 2020-08-12 Antibodies against ilt2 and use thereof
US202163145604P 2021-02-04 2021-02-04
US202163149371P 2021-02-15 2021-02-15
PCT/IB2021/057414 WO2022034524A2 (en) 2020-08-12 2021-08-11 Antibodies against ilt2 and use thereof

Publications (1)

Publication Number Publication Date
BR112023002301A2 true BR112023002301A2 (pt) 2023-10-03

Family

ID=80223922

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002301A BR112023002301A2 (pt) 2020-08-12 2021-08-11 Anticorpos contra ilt2 e uso dos mesmos

Country Status (13)

Country Link
US (1) US20220048991A1 (pt)
EP (1) EP4196227A2 (pt)
JP (1) JP2023537396A (pt)
KR (1) KR20230058074A (pt)
CN (1) CN116096756A (pt)
AU (1) AU2021325430A1 (pt)
BR (1) BR112023002301A2 (pt)
CA (1) CA3190634A1 (pt)
CO (1) CO2023002375A2 (pt)
IL (1) IL300588A (pt)
MX (1) MX2023001776A (pt)
TW (1) TW202221035A (pt)
WO (1) WO2022034524A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023170434A1 (en) * 2022-03-11 2023-09-14 Macomics Limited Compositions and methods for modulation of macrophage activity
CN116082500B (zh) * 2022-12-09 2023-08-22 珠海重链生物科技有限公司 抗SARS-CoV-2抗体nCoV1和nCoV2及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
EP3209769B1 (en) * 2014-10-24 2020-08-05 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
CN108884163B (zh) * 2016-01-21 2022-08-16 依奈特制药公司 对淋巴细胞中抑制途径的中和
EP3740224A4 (en) * 2018-01-18 2022-05-04 Adanate, Inc. ANTI-LILRB ANTIBODIES AND THEIR USES
AU2019412489A1 (en) * 2018-12-26 2021-06-10 Innate Pharma Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies

Also Published As

Publication number Publication date
EP4196227A2 (en) 2023-06-21
JP2023537396A (ja) 2023-08-31
CA3190634A1 (en) 2022-02-17
MX2023001776A (es) 2023-03-10
WO2022034524A2 (en) 2022-02-17
TW202221035A (zh) 2022-06-01
CO2023002375A2 (es) 2023-03-27
KR20230058074A (ko) 2023-05-02
WO2022034524A3 (en) 2022-04-28
US20220048991A1 (en) 2022-02-17
AU2021325430A1 (en) 2023-04-20
CN116096756A (zh) 2023-05-09
IL300588A (en) 2023-04-01

Similar Documents

Publication Publication Date Title
BR112022002579A2 (pt) Anticorpos contra ilt2 e uso dos mesmos
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
EA201891178A1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201991763A1 (ru) Конъюгаты антитела к ccr7 и лекарственного средства
BR112019018685A8 (pt) Anticorpos, composição farmacêutica, kit, usos de um anticorpo e método in vitro de identificação ou seleção de um anticorpo
MX2021004808A (es) Anticuerpos contra la epcam, anticuerpos activables e inmunoconjugados y usos de estos.
MA40913A (fr) Conjugués anticorps-médicament
BR112023002301A2 (pt) Anticorpos contra ilt2 e uso dos mesmos
BRPI0821658B8 (pt) anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos
EA202091747A1 (ru) Составы антитела b7-h4
BR112020015915A8 (pt) Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer
EA202092518A1 (ru) Композиции и способы лечения рака
BR112022000216A2 (pt) Anticorpos direcionados a dll3 e usos dos mesmos
WO2021227307A8 (zh) 抗cd73抗体及其用途
BR112019023909A2 (pt) método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio.
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
BR112022005465A2 (pt) Conjugados de proteína-macromolécula e métodos de uso dos mesmos
BR112021019107A2 (pt) Anticorpos contra amiloide-beta piroglutamato e usos dos mesmos
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
MX2022004058A (es) Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo.
BR112022003635A2 (pt) Anticorpo anti-vsig4 ou fragmento de ligação ao antígeno e seu uso
EA202092122A1 (ru) Антитела против tip-1 и их применения
BR112022020716A2 (pt) Anticorpos anti-tumor associados ao antígeno e usos dos mesmos
BR112022010826A2 (pt) Anticorpos amplamente neutralizantes contra o hiv